chufangao/CTO huggingface dataset:
Clinical trial NCT03892772: Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea
Official title: Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea
Acronym: ComboPlus
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-01-14
Primary completion date: 2021-07-03
Completion date: 2021-07-03
Plan to share individual participant data: YES
IPD sharing description: Will IPD be available? Yes What data will be shared? All IPD collected during the study, after deidentification.~When will data be available? Immediately after publication. No end date. With whom? Researchers who provide a methodologically sound proposal. For what types of analyses? Any purpose.
IPD time frame: Immediately after publication. No end date.
IPD access criteria: 1-page proposals should be directed to Dr. Scott Sands (sasands@bwh.harvard.edu). To gain access, requestors will be asked to sign a data use agreement.
Clinical trial NCT04389840: Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Official title: A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Sponsor: Chimerix (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Due to improvement in the Coronavirus Disease 2019 (COVID-19) pandemic and low subject accrual.
Enrollment: 27.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-07-08
Primary completion date: 2021-05-20
Completion date: 2021-05-20
Baseline population: Note: Baseline characteristics were evaluated for the Safety Analysis Set. The Intent-to-Treat Analysis Set included 4 placebo-treated subjects from Cohort 2; however, only 3 placebo-treated subjects from Cohort 2 were included in the Safety Analysis Set. The excluded subject was randomized to receive placebo but never received treatment due to consent withdrawal.
Limitations and caveats: Due to improvement in the Coronavirus Disease 2019 (COVID-19) pandemic and low subject accrual, study enrollment was prematurely terminated on 20 May 2021. Therefore, formal statistical analyses were not performed, and no conclusions can be drawn about docipartstat with regards to efficacy.
Plan to share individual participant data: NO
Clinical trial NCT04268069: Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye
Official title: A Phase 2, Multi-center, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of PL9643 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
Sponsor: ORA, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 160.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-14
Primary completion date: 2020-10-05
Completion date: 2020-10-05
Clinical trial NCT04812535: Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
Official title: Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)
Sponsor: InflaRx GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decided to stop the development of vilobelimab in cSCC and early terminates the IFX-1-P2.8 trial due to new alternative treatments for cSCC with high efficacy rates.
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-01
Primary completion date: 2024-06-04
Completion date: 2024-06-04
Clinical trial NCT02165813: Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children
Official title: A Randomised, Placebo-controlled Trial of Oral Nitazoxanide for the Empiric Treatment of Acute Gastroenteritis Among Australian Indigenous Children
Acronym: NICEGUT
Sponsor: Telethon Kids Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Continuation of enrolment was deemed not feasible due to very small eligibility numbers and funding exhausted.
Enrollment: 216.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-11-30
Primary completion date: 2021-04-21
Completion date: 2021-06-06
Clinical trial NCT04323436: Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
Official title: A Double-blind, Placebo Controlled, Randomized, Phase II Study Evaluating the Efficacy and Safety of Capmatinib and Spartalizumab vs Capmatinib and Placebo as 1st Line Treatment for Advanced NSCLC Patients With MET exon14 Skipping Mutations
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study termination based on sponsor decision due to lack of tolerability observed with capmatinib and spartalizumab combination treatment when compared to data from capmatinib single agent studies
Enrollment: 31.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-08-19
Primary completion date: 2022-12-14
Completion date: 2023-01-26
Baseline population: All patients to whom study treatment had been assigned and who received at least one dose of study treatment (i.e. at least one dose of any component of the study treatment that is capmatinib or spartalizumab). The randomized part of the study was not initiated.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT03690869: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Official title: A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 57.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-09-24
Primary completion date: 2023-05-10
Completion date: 2023-05-10
Limitations and caveats: As all efficacy cohorts for this study have now been closed due to the futility criteria, Regeneron as Sponsor in collaboration with PNOC made a decision to close the study to further enrollment.
Clinical trial NCT04635527: A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
Official title: A Phase Ib Study to Evaluate the Safety and Efficacy of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue the study after consultation with investigators.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-24
Primary completion date: 2021-08-27
Completion date: 2023-03-07
Clinical trial NCT03738423: Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Official title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 129.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-11-13
Primary completion date: 2020-03-13
Completion date: 2020-07-24
Baseline population: Full Analysis Set (FAS) included all randomized participants and was based on the treatment allocated (as randomized).
Limitations and caveats: The decision was made by the sponsor to terminate the study on 12 Feb 2020 due to lack of efficacy. Study enrollment was not complete at that time, therefore planned sample sizes were not met. Participants discontinued study drug and transitioned into the post-treatment follow-up period. As a result of the decision to terminate the study, all statistical analyses were descriptive and no hypothesis testing was performed.
Clinical trial NCT04400682: Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions
Official title: Open-label, Randomised, Single Oral Dose, Two-period, Cross-over Trial to Assess to Bioequivalence of Favira 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions
Acronym: Favipiravir
Sponsor: Novelfarma Ilaç San. ve Tic. Ltd. Sti. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-28
Primary completion date: 2020-06-05
Completion date: 2020-06-18
Clinical trial NCT04697758: Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
Official title: Phase 1/2a Study of the Safety and Bioactivity of AXT-107 in Subjects With Diabetic Macular Edema (DME)
Acronym: CONGO
Sponsor: AsclepiX Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Adverse Events
Enrollment: 6.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-12-10
Primary completion date: 2022-10-01
Completion date: 2022-10-01
Baseline population: Enrollment was closed after mid dose cohort were enrolled. The study only enrolled 6 subjects.
Clinical trial NCT05275673: A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Official title: A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Sponsor: Calithera Biosciences, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 7.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-04-15
Primary completion date: 2023-03-10
Completion date: 2023-03-10
Plan to share individual participant data: NO
IPD sharing description: We do not plan to share the individual participant data with other researchers
Clinical trial NCT03796195: (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes
Official title: Does Stellate Ganglion Blockade (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes? A Pilot Prospective Cohort Study
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Enrollment issues
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-13
Primary completion date: 2021-07-16
Completion date: 2021-07-16
Limitations and caveats: The study was closed early for slow enrollment.
Plan to share individual participant data: NO
Clinical trial NCT04232280: Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
Official title: A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults
Sponsor: ModernaTX, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 315.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-01-09
Primary completion date: 2023-01-04
Completion date: 2023-01-04
Plan to share individual participant data: NO
Clinical trial NCT04678505: Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)
Official title: An Open-Label Trial to Evaluate the Pharmacokinetics of MK-3402 Following Administration of a Single IV Dose to Participants With Mild, Moderate, and Severe Renal Impairment and End-Stage Renal Disease
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 9.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-02-10
Primary completion date: 2021-04-15
Completion date: 2021-04-27
Baseline population: The Baseline Analysis Population consists of participants in Panels A and B. The study was terminated early due to business reasons prior to enrollment of Panels C, D, and E; thus, no baseline characteristics are presented for healthy control participants and participants with severe RI or ESRD.
Limitations and caveats: Due to early study termination, some of the planned endpoints were not able to be completed.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03907813: Liposomal Bupivacaine After Cesarean Delivery
Official title: The Effect of Local Infiltration of Liposomal Bupivacaine on Opioid Consumption at Time of Cesarean Delivery: A Randomized Controlled Trial
Sponsor: Wright State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: change in design
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-01
Primary completion date: 2020-06-30
Completion date: 2020-07-31
Plan to share individual participant data: NO
IPD sharing description: Data will be shared on a case by case basis.
Clinical trial NCT04078191: Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA
Official title: A Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue From Subjects Clinically Diagnosed With Rheumatoid Arthritis (RA)
Sponsor: Navidea Biopharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision.
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-14
Primary completion date: 2024-07-09
Completion date: 2024-07-09
Clinical trial NCT04489446: Sildenafil in COVID-19
Official title: Sildenafil for Treating Patients With COVID-19 and Perfusion Mismatch: A Pilot Randomised Trial
Sponsor: Universidad Nacional Andres Bello (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-19
Primary completion date: 2021-04-30
Completion date: 2021-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05116683: ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
Official title: A Phase II Study, With a Safety lead-in, to Evaluate ATX-101, a Peptide Drug Targeting PCNA, in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
Acronym: ATX-101
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated by PI
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-01-11
Primary completion date: 2022-10-27
Completion date: 2022-10-27
Plan to share individual participant data: NO
Clinical trial NCT03063606: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
Official title: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-05
Primary completion date: 2021-12-01
Completion date: 2022-12-16
Clinical trial NCT03763734: High-Dose Steroid for Knee Arthroplasty Patients Expected to Have Postoperative Pain
Official title: High-Dose Steroids in High Pain Responders Undergoing Total Knee-arthroplasty: A Randomized Double Blinded Controlled Trial
Sponsor: Copenhagen University Hospital, Hvidovre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 88.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-29
Primary completion date: 2021-01-01
Completion date: 2021-01-01
Plan to share individual participant data: NO
Clinical trial NCT03982277: Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
Official title: A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
Acronym: SAEFRIF
Sponsor: Makerere University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 130.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-04-30
Primary completion date: 2021-03-16
Completion date: 2021-07-23
Plan to share individual participant data: YES
IPD sharing description: Individual patient data (IPD) will made available to other researchers for further analysis or met-analysis following direct request to the sponsor (Infectious Diseases Institute).
IPD time frame: 6 months after publication of study results.
IPD access criteria: Direct request shall be made to Infectious Diseases Institute for pooling of data and met-analysis
Clinical trial NCT04449380: Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients
Official title: Randomized, Controlled, Open Label, Phase 2 Clinical Trial of Interferon-β-1a (IFNβ-1a) in COVID-19 Patients
Acronym: INTERCOP
Sponsor: IRCCS San Raffaele (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Futility
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-02
Primary completion date: 2021-03-30
Completion date: 2021-03-30
Clinical trial NCT04659122: A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
Official title: Phase 1b Open-label, Single Arm, Cohort Dose Escalation Study Evaluating the Safety, Tolerability, and Feasibility of Intervention With AT-100 (rhSP-D) in Intubated Patients Receiving Invasive Mechanical Ventilation With Severe COVID-19 Infection or Respiratory Failure Secondary to Severe Community Acquired Pneumonia
Sponsor: Airway Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Termination / study goals reached
Enrollment: 5.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-08-17
Primary completion date: 2023-02-23
Completion date: 2023-02-23
Clinical trial NCT03408405: ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children
Official title: ADRENL - ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children, Pilot Study
Acronym: ADRENL
Sponsor: Rhode Island Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Withdrawal of funding from primary sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-30
Primary completion date: 2021-01-31
Completion date: 2021-07-31
Plan to share individual participant data: NO
Clinical trial NCT03881735: Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Official title: A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients With AML Harboring Mutations in IDH2 Who Have Failed or Been Refractory to One Prior Line of Therapy
Sponsor: Roswell Park Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: no accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-02
Primary completion date: 2021-11-19
Completion date: 2022-11-19
Clinical trial NCT04787731: Efficacy of Two Local Anesthetics on Quality of Life After Endodontic Treatment
Official title: Efficacy of Two Dental Local Anesthetics on the Oral Health-Related Quality of Life After Endodontic Treatment in the Symptomatic Mandibular Molars: A Double Blind Randomized Controlled Trial
Acronym: B-OHIP14
Sponsor: NYU College of Dentistry (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: COVID-19 and Personnel changes
Enrollment: 100.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-07-29
Primary completion date: 2024-10-01
Completion date: 2024-10-01
Plan to share individual participant data: NO
Clinical trial NCT04141930: Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle
Official title: Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle (pCHIMES)
Acronym: pCHIMES
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 481.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-01
Primary completion date: 2020-04-01
Completion date: 2020-04-01
Baseline population: Based on individuals that contributed data during the test-and-treat phase of the protocol.
Plan to share individual participant data: NO
IPD sharing description: We do not currently expect to share specimens with outside investigators, but if compelling opportunities arise that will advance the overall objectives of this research, the Executive Committee of the study will consider such requests. They alone have the authority to make such decisions.~All biospecimens (nasal swabs) will be coded and identifiable through the study's main database. Any specimens shared with external investigators (if deemed appropriate by the Executive Committee) will have identifiers removed prior to sharing.
Clinical trial NCT04228445: 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
Official title: An Open-Label Study of Two Different Doses of 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution When Used as an Aid for Ureteral Patency
Acronym: UP
Sponsor: Prove pharm (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 121.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-02-13
Primary completion date: 2021-06-03
Completion date: 2021-06-03
Baseline population: Population presented is the Safety Analysis Set, while the population presented in the Participant Flow was the all randomized population
Plan to share individual participant data: NO
Clinical trial NCT04353505: Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
Official title: Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: PI closed the study before any enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-31
Primary completion date: 2022-06-30
Completion date: 2023-06-30
Plan to share individual participant data: NO